Last reviewed · How we verify
Bromodeoxyuridine (BROXURIDINE)
Bromodeoxyuridine (generic name: BROXURIDINE) is a broxuridine drug. It is currently in Phase 2 development.
Bromodeoxyuridine works by mimicking the structure of thymidine, a building block of DNA, and inhibiting the action of thymidine kinase, an enzyme essential for viral DNA replication.
Bromodeoxyuridine is a small molecule used in clinical trials for various conditions, including stage I and II prostate cancer, cytogenetic abnormalities, and radiation exposure. It has been studied in combination with conventional surgery and laboratory biomarker analysis in these trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BROXURIDINE |
|---|---|
| Drug class | broxuridine |
| Target | Thymidine kinase, cytosolic, Thymidylate kinase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like factories that build new DNA. Bromodeoxyuridine is a fake building block that gets in the way of the factory's machinery, preventing the virus from making more copies of itself. This can help slow down or stop the spread of the virus.
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia (PHASE2)
- Genomic Instability in Vascular Surgeons
- Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients
- Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer (PHASE2)
- IUdR/BUdR Cell Cycle Labelling (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bromodeoxyuridine CI brief — competitive landscape report
- Bromodeoxyuridine updates RSS · CI watch RSS
Frequently asked questions about Bromodeoxyuridine
What is Bromodeoxyuridine?
How does Bromodeoxyuridine work?
What is the generic name of Bromodeoxyuridine?
What drug class is Bromodeoxyuridine in?
What development phase is Bromodeoxyuridine in?
What does Bromodeoxyuridine target?
Related
- Drug class: All broxuridine drugs
- Target: All drugs targeting Thymidine kinase, cytosolic, Thymidylate kinase
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing